A peptide selected by biopanning identifies the integrin αvβ6 as a prognostic biomarker for nonsmall cell lung cancer

Anissa N. Elayadi, Kausar N. Samli, Ludmila Prudkin, Ying Horng Liu, Aihua Bian, Xian Jin Xie, Ignacio I. Wistuba, Jack A. Roth, Michael J. McGuire, Kathlynn C. Brown

Research output: Contribution to journalArticlepeer-review

130 Scopus citations


The development of new modes of diagnosis and targeted therapy for lung cancer is dependent on the identification of unique cell surface features on cancer cells and isolation of reagents that bind with high affinity and specificity to these biomarkers. We recently isolated a 20-mer peptide which binds to the lung adenocarcinoma cell line, H2009, from a phage-displayed peptide library. We show here that the cellular receptor for this peptide, TP H2009.1, is the uniquely expressed integrin, αvβ 6, and the peptide binding to lung cancer cell lines correlates to integrin expression. The peptide is able to mediate cell-specific uptake of a fluorescent nanoparticle via this receptor. Expression of α vβ6 was assessed on 311 human lung cancer samples. The expression of this integrin is widespread in early-stage nonsmall cell lung carcinoma (NSCLC). Log-rank test and Cox regression analyses show that expression of this integrin is significantly associated with poor patient outcome. Preferential expression is observed in the tumors compared with the surrounding normal lung tissue. Our data indicate that αvβ 6 is a prognostic biomarker for NSCLC and may serve as a receptor for targeted therapies. Thus, cell-specific peptides isolated from phage biopanning can be used for the discovery of cell surface biomarkers, emphasizing the utility of peptide libraries to probe the surface of a cell.

Original languageEnglish (US)
Pages (from-to)5889-5895
Number of pages7
JournalCancer research
Issue number12
StatePublished - Jun 15 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A peptide selected by biopanning identifies the integrin α<sub>v</sub>β<sub>6</sub> as a prognostic biomarker for nonsmall cell lung cancer'. Together they form a unique fingerprint.

Cite this